Clovis Oncology (NASDAQ:CLVS) Receives $9.50 Consensus Price Target from Brokerages


Share on StockTwits

Clovis Oncology (NASDAQ:CLVS) has been assigned an average rating of “Hold” from the six brokerages that are presently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and two have issued a buy recommendation on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $9.50.

Separately, HC Wainwright decreased their target price on Clovis Oncology from $15.00 to $13.00 and set a “buy” rating for the company in a research report on Tuesday, February 23rd.

In related news, insider Gillian C. Ivers-Read sold 10,990 shares of the firm’s stock in a transaction that occurred on Tuesday, February 2nd. The stock was sold at an average price of $7.97, for a total value of $87,590.30. Also, insider Thomas C. Harding sold 7,367 shares of Clovis Oncology stock in a transaction on Friday, March 12th. The shares were sold at an average price of $5.99, for a total value of $44,128.33. The disclosure for this sale can be found here. Company insiders own 6.60% of the company’s stock.

Institutional investors have recently made changes to their positions in the business. Chiron Capital Management LLC bought a new stake in Clovis Oncology during the 3rd quarter valued at $40,000. ProShare Advisors LLC bought a new stake in Clovis Oncology during the 3rd quarter valued at $59,000. GWM Advisors LLC bought a new stake in Clovis Oncology during the 4th quarter valued at $56,000. WealthTrust Axiom LLC raised its stake in shares of Clovis Oncology by 20.0% in the 4th quarter. WealthTrust Axiom LLC now owns 12,000 shares of the biopharmaceutical company’s stock worth $57,000 after buying an additional 2,000 shares in the last quarter. Finally, Point72 Hong Kong Ltd raised its stake in shares of Clovis Oncology by 3,812.6% in the 3rd quarter. Point72 Hong Kong Ltd now owns 14,907 shares of the biopharmaceutical company’s stock worth $87,000 after buying an additional 14,526 shares in the last quarter. 57.83% of the stock is currently owned by hedge funds and other institutional investors.

Shares of CLVS traded down $0.20 during mid-day trading on Monday, hitting $5.78. The stock had a trading volume of 3,717,042 shares, compared to its average volume of 12,537,028. The company has a market cap of $604.18 million, a PE ratio of -1.10 and a beta of 2.10. The company’s fifty day simple moving average is $6.33 and its two-hundred day simple moving average is $5.89. Clovis Oncology has a fifty-two week low of $4.08 and a fifty-two week high of $11.10.

Clovis Oncology (NASDAQ:CLVS) last issued its earnings results on Monday, February 22nd. The biopharmaceutical company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.26). The firm had revenue of $43.30 million during the quarter, compared to the consensus estimate of $43.16 million. On average, equities analysts anticipate that Clovis Oncology will post -3.93 earnings per share for the current year.

About Clovis Oncology

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.

Featured Article: What is a management fee?

Analyst Recommendations for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.